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Available online 3 May 2016AbstractBackground: This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemo-
therapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC).
Methods: A total of 50 consecutive GC PC patients treated by 52 CRSþHIPEC procedures with lobaplatin 50 mg/m2 and docetaxel 60 mg/
m2 in 6000 mL of normal saline at (43  0.5) C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints
were perioperative safety profiles.
Results: At the median follow-up of 22.5 (range, 5.1e50.7) months, the median OS was 14.3 (95% CI 7.6e21.0) months, and the 1-, 2-, and
3-year survival rates were 58%, 40%, and 32%, respectively. Mortality and serious adverse event (grade 3e5) morbidity rates in postop-
erative 30 days were 0.0% and 23.1%, respectively. Univariate analysis identified 4 parameters with significant effects on OS: completeness
of cytoreduction (CC) 0e1, normal (N) the preoperative tumor markers level (TM), adjuvant chemotherapy 6 cycles, and peritoneal can-
cer index 20. However, multivariate analysis identified CC0-1, perioperative TM (N), adjuvant chemotherapy 6 cycles as the indepen-
dent predictor for better survival.
Conclusions: CRSþHIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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chemotherapyIntroduction
Gastric cancer (GC) accounts for 10% of cancer-related
deaths,1 and China accounts for over 40% of all new cases
worldwide.2,3 Approximately 30% of patients have
regional spread at diagnosis,4 and the locoregionalhor. Department of Peritoneal Cancer Surgery, Bei-
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).progression of GC generally results in peritoneal carcino-
matosis (PC), characterized by the presence of tumor nod-
ules of various size, number, and distribution on the
peritoneal surface. PC renders significant negative impact
on survival and quality of life as a result of refractory as-
cites, progressive intestinal obstruction, and uncontrolla-
ble abdominal pain. The traditional therapies for such
patients are systemic chemotherapy, palliative surgery,
and best support care. The prognosis for GC PC is the
worst among its recurrence patterns, with a median sur-
vival of less than 6 months.5cess article under the CC BY-NC-ND license (http://creativecommons.org/
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tumor biology and treatment technology improvements, the
knowledge of PC has also changed considerably, and PC is
regarded as locoregional disease rather than widespread
metastasis. Therefore, novel therapies to PC have emerged,
combining cytoreductive surgery (CRS) plus hyperthermic
intraperitoneal chemotherapy (HIPEC), which have the ad-
vantages of surgery to remove the bulky visible tumor burden
and regional hyperthermic chemotherapy to eradicate micro-
metastases and invisible free tumor cells. Up to now, accumu-
lating clinical evidence-based data demonstrate that
CRSþHIPEC is the most effective strategy to treat selected
PC patients from colorectal cancer,6 pseudomyxoma perito-
nei,7 epithelial ovarian cancer,8 and gastric cancer.9,10 We
have conducted experimental11 and clinical12 studies to
prove the safety and effectiveness of CRSþHIPEC for GC
PC therapy. A phase III randomized clinical trial, in synchro-
nous GC PC, demonstrates that CRSþHIPEC could prolong
OS nearly twice as much as single CRS (12.0 months vs. 6.5
months).10 Therefore, CRSþHIPEC is evolving as an effec-
tive comprehensive treatment strategy for PC.13
The chemotherapeutic regimens on HIPEC are varied
without standard operating procedures atmany centers around
the world, including mitomycin, cisplatin, carboplatin, oxali-
platin, docetaxel, paclitaxel, andfluorouracil.6,13,14Hyperther-
mia and chemotherapy have synergistic effect, which is
dramatically enhanced at 42 C.15e17 Lobaplatin is a represen-
tative of the third-generation platinum compounds, induces
the formation of inter-strand Pt-GG and Pt-AG crosslinks, to
hinder DNA replication and transcription thereby inhibiting
gene expression in tumor cells.18 Lobaplatin has demonstrated
several advantageous properties, including strong antineo-
plastic activity, no significant nephrotoxicity or neurotox-
icity,19 no cross-resistance with cisplatin,20 and relatively
bigger molecular mass than other platinum drugs with phar-
macokinetics advantages in intraperitoneal chemotherapy. A
previous basic research has been verified that lobaplatin in-
hibits GC cells by inducing apoptosis, which supports the po-
tential use of lobaplatin to treat GC.21 A clinical observational
study demonstrated that lobaplatin used in intrapleural or
intraperitoneal infusion is a safe and effective treatment for pa-
tients with malignant pleural effusion or ascites.22
A phase I/II clinical researches of lobaplatin in combina-
tion with docetaxel have demonstrated an acceptable safety
and efficacy for various malignant solid tumors.23,24 Lobapla-
tin and docetaxel also demonstrated synergistic antineoplastic
effects when used in combination.25 Therefore, we summarize
our experience in 52CRSþHIPECprocedureswith lobaplatin
and docetaxel to treat 50 GC PC patients at our center.
Patients and methodsPatients selectionThis is a retrospective study on prospectively established
database. Between July 2011 and December 2014, a total of50 consecutive Chinese patients including 22 males and 28
females with GC PC underwent 52 CRSþHIPEC proce-
dures. The inclusion criteria were: (1) age 20e75 years
old; (2) Karnofsky performance status >50; (3) peripheral
blood white blood cells count 3500/mm3 and platelet
count 80,000/mm3; (4) acceptable liver function, with
bilirubin 2 times the upper limit of normal (ULN), and as-
partic aminotransferase and alanine aminotransferase
2  ULN; (5) acceptable renal function, with serum
creatinine 1.5 mg/dl; and (6) cardiovascular pulmonary
and other major organ functions could stand major opera-
tion. Major exclusion criteria were: (1) age <20 years or
>75 years; (2) any lung metastasis, liver metastasis, or
prominent retroperitoneal lymph node metastasis during
preoperative assessment; (3) serum bilirubin level
>3  ULN; (4) liver enzymes >3  ULN; and (5) serum
creatinine level >1.5 mg/dl. Written informed consent was
obtained from all patients and the study was approved by
the institutional review board and the ethics committee.CRSþHIPEC procedureAll CRSþHIPEC procedures were performed by a
designated team of surgical oncologist, anesthesiologist,
and operating room staff concentrating on PC therapy,
with detailed description reported previously.10,12 After
anesthesia, the Expression Sequential Compression System
Vascular Refill Detection device was wrapped to both legs
for preventing deep vein thrombosis due to long operation
time. The abdominal exploration was conducted under gen-
eral anesthesia and stable hemodynamic monitoring,
through a midline xiphoid-pubic incision, and detailed
assessment of peritoneal cancer index (PCI) in accordance
with Sugarbaker’s criteria.26 Then maximal CRS was per-
formed to remove the primary and metastatic tumor with
acceptable margins, any involved adjacent structures, peri-
tonectomy, and regional lymph nodes where peritoneal sur-
faces were involved by tumor metastasis.26 The extent of
CRS was determined according to the principle of Sugar-
baker on the completeness of cytoreduction (CC)27 before
HIPEC. A score of CC-0 indicates no residual peritoneal
disease after CRS; CC-1 represents less than 2.5 mm of re-
sidual disease; CC-2 indicates residual tumor between
2.5 mm and 2.5 cm; and CC-3 means more than 2.5 cm
of residual tumor or the presence of a sheet of unresectable
tumor nodules.
After CRS, abdominal cavity was fully open by an
extractor so as to create adequate space for HIPEC drugs.
All-layer surgical incision protector covered the open
abdomen in order to keep the temperature stable and avoid
HIPEC drugs diffusing in the air. The HIPEC was delivered
by the open coliseum technique as it could provide optimal
thermal homogeneity and spatial diffusion,26 with 50 mg/
m2 of lobaplatin and 60 mg/m2 of docetaxel each dissolved
3 L of normal saline. The perfusion solution was kept at
43.0  0.5 C, temperature probes were placed on the
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toring, and the perfusion rate was 400 mL/min. The total
HIPEC time was 60 min. After HIPEC, gastro-intestinal
anastomoses and/or stoma were made. The incision was
closed with a tension-reduced suture. After surgery, the pa-
tient was transferred to the intensive care unit for recovery.
When the vital signs stabilized, the patient was transferred
to general surgical oncology ward.Postoperative chemotherapyPostoperative adjuvant chemotherapy included intraper-
itoneal chemotherapy (IP) through the IP port mainly using
lobaplatin (50 mg/m2, on day 1, every 21 days) and doce-
taxel (60 mg/m2, on day 1, every 21 days), and systemic
chemotherapy (SC) mainly with FOLFOX (oxaliplatin, leu-
covorin, and 5-fluorouracil) regimens. All dosed according
to body surface area calculation.6,26Study endpoints and definitionThe primary endpoint of this study was the overall sur-
vival (OS), defined as time interval from the first CRSþHI-
PEC to death due to any cause. The secondary endpoints
were the perioperative serious adverse events (SAE),
defined as severe local and/or systemic infection, intestinal
or anastomotic leakage, intestinal obstruction, hemorrhage,
or death related to the procedure within 30 days of
CRSþHIPEC, based on NCI Common Terminology
Criteria (CTC) for Adverse Events version 4.0.28
The following definitions were used to define the
terms in this study: 1) Perioperative period: from the
day of CRSþHIPEC to day 30 postoperation; 2) Syn-
chronous PC: PC was diagnosed synchronously at first
treatment; 3) PCI 20 was defined as low PCI (LPCI),
and PCI >20 was defined as high PCI (HPCI)27; 5)
The current research defined CC0-1 as complete cytore-
duction, and CC2-3 as incomplete cytoreduction.27 6) Tu-
mor markers (TM) included carcinoembryonic antigen
(CEA), cancer antigen 125 (CA125), and cancer antigen
199 (CA199); normal (N) means within the upper limit
of normal value; abnormal (AN) means over upper limit
of normal value.Follow-upAll patients underwent routine postoperative follow-up
with physical examination, chest and abdominopelvic
computed tomography, serum tumor markers, including
CEA, CA125, and CA199 every 3 months during the first
2 years, and then every 6 months thereafter by outpatients
consultation or by telephone. The most recent follow-up
was on October 8, 2015, and no patient was lost for
follow-up.Statistical analysisAll data were systematically collected to establish a
comprehensive database of clinical records, surgical and
pathology reports, image examination and laboratory re-
ports, and follow-up records. The data were analyzed by
SPSS software for windows, version 20.0 (SPSS Inc., Chi-
cago, IL, USA). The KaplaneMeier survival curve was
plotted for survival analysis, the log rank test was utilized
to identify difference between curves, and multivariate
Cox regression analysis was conducted to discriminate
the independent predictors. A two-sided P < 0.05 was
considered as statistically significant.
ResultsMajor clinicopathological characteristics, surgical
intervention, and perioperative treatmentA total of 50 patients underwent 52 CRSþHIPEC treat-
ments between July 2011 and December 2014, including 2
patients with twice CRSþHIPEC procedures because of tu-
mor recurrence. Major clinicopathological characteristics
of the patients were listed in Table 1. The median time to
nasogastric tube removal was 5 (range, 2e17) days, to
liquid food intake was 6 (range, 3e18) days, to drainage
tubes removal were 5 (range, 2e17) days, to sutures
removal was 15 (range, 10e25) days.
CRSþHIPEC procedures and major intraoperative pa-
rameters included fluid output and intake volume, duration
of surgery, and fluid balance parameters. The median oper-
ation time was 400 (range, 230e720) min. During surgery,
the median volume of blood loss, ascites and urine output
were 500 (range, 100e4000) mL, 300 (range, 0e5000)
mL, and 1500 (range, 200e3000) mL, respectively; and
the median transfusion volume of red blood cell, plasma,
cryoprecipitation and other fluids were 400 (range,
0e1200) mL, 450 (range, 0e4000) mL, 200 (range,
0e350) mL, and 3500 (range, 300e6500) mL, respectively.
After operation, 22 patients received a median of 6
(range, 1e12) cycles of SC and 22 patients received a me-
dian of 6 (range, 2e13) cycles of IPþSC procedures. The
other patients did not receive adjuvant chemotherapy
because of intestinal leakage (n ¼ 1), intestinal obstruction
(n ¼ 1), cachexia (n ¼ 2), and refusing any chemotherapy
(n ¼ 2).Survival analysisThe median follow-up time was 22.5 (range, 5.1e50.7)
months. The median OS was 14.3 (95% CI, 7.6e21.0)
months (Fig. 1A). The 1-, 2-, 3-year OS rates were
58.0%, 40.0%, and 32.0%, respectively. The median OS
for CC0-1 vs. CC2-3 was 23.5 (95% CI, 18.5e28.5) months
vs. 8.0 (95% CI, 7.4e8.6) months (P ¼ 0.000, log rank test)
(Fig. 1B). The median OS for preoperative TM (N) vs. TM
Table 1
Major clinico-pathologic characteristics of the 50 GC PC patients.a
Items Value, n (%)
Gender
Male/Female 22/28 (44/56)
Age (years)
<60/60 33/17 (66/34)
Median KPS score (range) 80 (60e90)
Histopathology
Adenocarcinoma 36 (72)
Undifferentiated/Mucous/Signet-ring cell carcinoma 14 (28)
Neoadjuvant chemotherapy
Yes/No 28/22 (56/44)
PCI scoresb
20/>20 29/21 (58/42)
Median PCI scores (range) 15 (3e35)
Ascites at surgeryb
1000/>1000 mL 34/16 (68/32)
Surgical procedures-organ resection
Partial/Total gastrectomy 42 (84)
Right colectomy 22 (44)
Transverse colectomy 5 (10)
Left colectomy Descending colectomy 8 (16)
Rectectomy 10 (20)
Resection ovarian/fallopian tube 16 (32)
Hysterectomy 6 (12)
Splenectomy 6 (12)
Cholecystectomy 3 (6)
Number of organ resectedb,c
1e3 resections 35 (76.1)
4e10 resections 11 (23.9)
Peritonectomyb
Greater/Lesser Omentum 49 (98)
Left diaphragmatic copula 8 (16)
Right diaphragmatic copula 13 (26)
Right colon gutter 10 (20)
Left colon gutter 16 (32)
Liver round ligament/sickle ligament 27 (54)
Douglas/rectovesical pouch 13 (26)
Anterior wall peritoneum 12 (24)
Pelvic peritoneum 17 (34)
Mesenteric fulguration 21 (42)
CC scoresb
0e1 32 (64)
2e3 18 (36)
Number of anastomosisb
None or ostomy only 6 (12)
¼1 4 (8)
>1 40 (80)
Postoperative chemotherapyd
SC/SCþPIC 22/22 (50/50)
Postoperative chemotherapy cyclesd
<6/6 18/26 (40.9/59.1)
PC: peritoneal carcinomatosis; KPS: Karnofsky performance scale; PCI:
peritoneal cancer index; CC: completeness of cytoreduction; SC: systemic
chemotherapy; PIC: postoperative intraperitoneal chemotherapy.
a 2 patients with secondary operation.
b According to the first surgery.
c 4 patients without organ resection.
d 6 patients without any postoperative chemotherapy.
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CI, 7.2e10.4) months (P ¼ 0.000, log rank test)
(Fig. 1C). The median OS for postoperative chemotherapy
6 cycles vs. <6 cycles was 26.0 (95% CI, 17.2e34.8)months vs. 8.0 (95% CI, 5.2e10.8) months (P ¼ 0.000,
log rank test) (Fig. 1D). The median OS for LPCI vs.
HPCI was 21.0 (95% CI, 13.7e28.3) months vs. 9.2
(95% CI, 6.0e12.4) months (P ¼ 0.013, log rank test)
(Fig. 1E). The median OS for postoperative SCþIP vs.
SC was 16.0 (95% CI, 8.4e23.6) months vs. 20.5 (95%
CI, 12.7e28.3) months (P ¼ 0.965, log rank test) (Fig. 1F).Special analysis of the patients on long-term
survivorsBy the time of last follow-up, there were 12 patients
(24%) with OS over 20 months (Table 2) and a median
OS of 24.8 months (ranging from 20.5 to 38.0 months).
Four patients with LPCI and CC-0 resection had disease
free survivals (DFS) of 28.1, 23.3, 23.2 and 20.6 months,
respectively. The other 8 patients died of tumor recurrence,
including 5 patients with LPCI and CC-0 resection, and 3
patients with HPCI and CC-1 resection.Serious adverse events (SAE)SAE (grades 3e5) occurred in 12 (23.1%) of 52
CRSþHIPEC procedures, including hypoalbuminemia
(grade 3, n ¼ 4), postoperative intestinal obstruction (grade
3, n ¼ 3), septicemia (grade 4, n ¼ 2), intestinal leakage
(grade 4, n ¼ 1), diarrhea (grade 3, n ¼ 1), vomit (grade
3, n ¼ 1).
The 90-day postoperative mortality occurred in 4 pa-
tients (8.0%). The first patient developed serious gastric-
jejunum anastomosis fistula and sigmoid-rectum anasto-
mosis fistula on postoperative day 8, generalized peritonitis,
peritoneal abscess formation and septicemia because of
Staphylococcus aureus and Candida tropicalis infection.
With flushing abdominal cavity, intraperitoneal drainage,
antibiotics, and total parenteral nutrition support, the pa-
tient survived 2.3 months after the operation. The other pa-
tients underwent palliative surgery without gastrectomy,
and survived 1.9, 2.0, 2.4 months respectively.
A binary logistic regression analysis was conducted to
study the correlation of SAEs with major treatment parame-
ters. Therewas no significant correlations between SAEs and
age, gender, histopathology differentiation, organ and perito-
neal resection region, PCI and CC score, operation duration.Univariate and multivariate analysis on predictors of
overall survivalTen parameters were included for univariate analysis
(Table 3), and 4 covariates indicative of improved survival
including CC0-1, TM (N), chemotherapy cycles 6, PCI
20.
Multivariate Cox regression analysis identified CC0-1,
TM (N), and chemotherapy cycles 6 as the independent
predictors for better survival. Compared with CC2-3, TM
(AN), and cycles <6, CC0-1, TM (N), and cycles 6
Figure 1. KaplaneMeier survival curves. The diseases overall survival in patients with GC PC treated by CRSþHIPEC (A). And The statistical significance
in overall survival (OS) comparisons stratified by CC (B), TM (C), postoperative adjuvant chemotherapy (D) and PCI (E). However, chemotherapy modes
were not statistically significant (F). OS: overall survival; mo: months; CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; PC:
peritoneal carcinomatosis; GC: gastric cancer; CC: completeness of cytoreduction; TM: tumor marker; N: normal; AN: above normal; PCI: peritoneal cancer
index; SC: systemic chemotherapy; IP: intraperitoneal chemotherapy.
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0.11e0.97, P < 0.044), 3 times (Hazard Ratio ¼ 3.05,
95% CI 1.17e7.95, P < 0.022), and 3 times (Hazard
Ratio ¼ 2.75, 95% CI 1.09e6.95, P < 0.033) more likely
to improve survival.
Discussion
In this clinical trial, we conducted 52 CRSþHIPEC pro-
cedures on 50 patients with synchronous GC PC, obtaining
1-, 2-, 3-year OS rates of 58.0%, 40.0%, and 32.0%, respec-
tively. And all the 12 long-terms survivors with OS over 20
months, including 4 patients still DFS at the last follow-up.Special analysis of these patients reveals several features.
First, these patients were relatively old with a median age
of 61 (range, 31e73) years. Similar study also revealed
that the elderly (65 years old) had superior survival (38.5
vs. 33 months) outcomes than the young (<65 years old)
without statistical significance.29 This could suggest that
old age itself is not a contraindication for CRSþHIPEC. Sec-
ond, these patients had relatively low PCI and CC at the time
of first surgery. Among the 12 cases, 9 patients had PCI<10
and CC-0, the others patients had HPCI and CC-1. Only 1 pa-
tient had CC 2 at the second CRSþHIPEC treatment. Third,
all the patients received relativelymore chemotherapy with a
median 8 cycles (ranging 2e13). These results support the
Table 2
Major treatment and follow-up features of patients with OS >20 months.
No. Gender/age
(yr)
PCI Histopathology CRS CC Survival (months) Comments
1 F/73 4 Adenocarcinoma,
well differentiated
Total gastrectomy, greater and lesser
omentum, liver round ligament
0 38.0, D
2 F/72 28 Adenocarcinoma,
well differentiated
Total gastrectomy, right
hemicolectomy, sigmoidectomy,
rectomy, hysterectomy, bilateral
adnexectomy, greater and lesser
omentum, liver round ligament, right
diaphragmatic copula peritoneum,
left and right colon gutter
peritoneum, Douglas/rectovesical
pouch, pelvic peritoneum, mesenteric
fulguration
1 29.5, D
3 M/45 First:23
Second: 19
Mucous carcinoma The first surgery: total gastrectomy,
greater and lesser omentum, liver
round ligament, left and right colon
gutter peritoneum, Douglas/
rectovesical pouch, Anterior wall
peritoneum, mesenteric fulguration
The second surgery: right and left
diaphragmatic copula peritoneum,
pelvic peritoneum; received HIPEC
as before
First:1
Second:3
29.1, D No extensive
abdominal adhesion
was found at the
second surgery
4 M/51 3 Mucous carcinoma Partial gastrectomy, greater and
lesser omentum
0 28.1, DFS
5 F/57 3 Adenocarcinoma,
well differentiated
Total gastrectomy, greater and lesser
omentum
0 26.0, D
6 F/37 1 Adenocarcinoma,
poorly/intermediately
differentiated
Total gastrectomy, greater and lesser
omentum
0 26.0, D
7 F/45 24 Signet-ring cell
carcinoma
Total gastrectomy, right
hemicolectomy, rectomy,
splenectomy, hysterectomy,
cholecystectomy, bilateral
adnexectomy, greater and lesser
omentum, liver round ligament, right
and left diaphragmatic copula
peritoneum, left colon gutter
peritoneum, Douglas/rectovesical
pouch, pelvic peritoneum, mesenteric
fulguration
1 23.5, D
8 M/51 3 Adenocarcinoma,
poorly/intermediately
differentiated
Partial gastrectomy, greater and
lesser omentum
0 23.3, DFS
9 M/70 3 Adenocarcinoma,
poorly/intermediately
differentiated
Partial gastrectomy, greater and
lesser omentum
0 23.2, DFS
10 F/59 5 Adenocarcinoma,
poorly/intermediately
differentiated
Total gastrectomy, bilateral
adnexectomy, greater and lesser
omentum
0 21.0, D SAE: Grade 4
vomit on postoperative
8 days, recovered after
20 days by conservative
therapy
11 F/62 3 Adenocarcinoma,
poorly/intermediately
differentiated
Partial gastrectomy, greater and
lesser omentum
0 20.6, DFS
12 M/66 21 Mucous carcinoma Total gastrectomy, right
hemicolectomy, rectomy, greater and
lesser omentum, liver round
ligament, right diaphragmatic copula
peritoneum, right colon gutter
peritoneum, Douglas/rectovesical
pouch, pelvic peritoneum, mesenteric
fulguration
0 20.5, D
M: male; F: female; D: died; DFS: disease free survival; SAE: serious adverse event.
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Table 3
Analysis of independent factors influencing OS.
Covariate Univariate analysis Multivariate analysis
c2 P HR 95% CI c2 P HR 95% CI
CC score (CC0-1 vs. CC2-3) 22.325 0.000 8.547 0.048e0.285 4.065 0.044 3.115 0.106e0.969
TM (N vs. AN) 13.665 0.000 4.236 1.970e9.108 5.212 0.022 3.051 1.171e7.948
Postoperative chemotherapy cycles (6 vs. <6) 12.456 0.000 3.897 1.831e8.295 4.564 0.033 2.748 1.087e6.948
PCI (<20 vs. 20) 5.676 0.017 2.299 0.219e0.863 0.011 0.915 2.188 0.457e2.017
SAE (no vs. yes) 1.170 0.279 1.705 0.648e4.486
Gender (male vs. female) 1.738 0.187 1.613 0.792e3.284
Ascites (1000 mL vs. >1000 mL) 0.212 0.645 1.190 0.400e1.765
NACT (yes vs. no) 0.072 0.788 1.098 0.556e2.170
Adjuvant chemotherapy IP (yes vs. no) 0.015 0.902 1.050 0.479e2.302
Age (<60 vs. 60) 0.003 0.959 1.019 0.478e2.015
OS: overall survival; CC: completeness of cytoreduction; TM: tumor market; N: normal; AN: above normal; PCI: peritoneal cancer index; SAE: serious
adverse events; NACT: neoadjuvant chemotherapy; HR: Hazard Ratio; CI: confidence interval. A two-sided P < 0.05 (in bold) was considered as statistically
significant.
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abdominopelvic visible tumor, and the synergistic effects of
HIPEC to eradicate residual tumor nodules, micrometastases
and free cancer cells.
The peritoneal-plasma barrier restricts the absorption of
large molecule drugs for peritoneum, and ensures high con-
centration of drugs in the abdominal cavity to eliminate re-
sidual small cancer nodules. Tissue penetration of
intraperitoneal chemotherapy is improved by moderate hy-
perthermia (41e42 C).15e17 As a result, HIPEC increases
the direct cytotoxic effects of chemotherapeutic drugs on
peritoneal surface tumors, and reduces the systemic side-
effect. Lobaplatin and docetaxel have relative molecular
mass larger than other platinum drugs and paclitaxel with
the advantage of pharmacokinetics in intraperitoneal
chemotherapy. A phase I clinical trial demonstrated that lo-
baplatin (35 mg/m2) combined with docetaxel (60 mg/m2)
to treat human solid tumors could exhibit short-term effi-
cacy with a low incidence of SAE.23 A phase II study of
lobaplatin (30 mg/m2) in combination with docetaxel
(75 mg/m2) demonstrated clinical activity and an accept-
able toxicity profile in recurrent and metastatic nasopharyn-
geal carcinoma24; and intrapleural or intraperitoneal
infusion of lobaplatin (20e30 mg/m2) is a safe treatment
for patients with malignant pleural effusion or ascites
with mild adverse event.22 In this study, CRSþHIPEC
with lobaplatin (50 mg/m2) and docetaxel (60 mg/m2) to
treat GC PC certified effective survival outcomes and an
acceptable safety. The study provided a new and effective
HIPEC option for GC PC treatment.
To our knowledge, there have been about 12 clinical
studies (Table 4) on the therapy of GC PC, including 7
phase II trials,9,12,29e33 1 phase III trial,10 3 controlled clin-
ical trials,34e36 and 1 systematic review.37 In 7 phase II tri-
als on 350 patients, the HIPEC was delivered at
temperature 41e48 C for 60e120 min, with mitomycin,
hydroxycamptothecin, cisplatin and oxaliplatin as the
frequently used drug. The median OS ranged from 9.2 to
14.3 months, with 1- and 5-year survival rates reaching50% and 16% at the maximum. The morbidity (grades
3e5) ranged from 14.3% to 62.5%, and mortality rate up
to 10% during perioperative period. The 3 controlled clin-
ical trials all demonstrated better survival for CRSþHIPEC
group than CRS alone, with acceptable SAEs. In the only
phase III randomized clinical trial of GC PC, the median
OS was 11.0 months in CRSþHIPEC group vs. 6.5 months
in CRS group with a median PCI 15. In a large sample-size
multicenter systematic review of GC PC patients, which
contained 10 original studies with 441 patients receiving
CRSþHIPEC procedures, the median of OS was 7.9
(range, 6.1e9.2) months, the 1-, 2-, 5-year survival rates
were 43%, 18%, and 13%, respectively, and the morbidity
(grade 3e5) and mortality rates were 21.5% and 4.8%.
In this study, univariate analysis identified 4 parameters
with significant effects on OS: CC0-1, perioperative TM
(N), adjuvant chemotherapy 6 cycles, (PCI) 20. Howev-
er, multivariate analysis identified CC0-1, perioperative TM
(N), adjuvant chemotherapy 6 cycles as the independent
predictor for better survival. PCI reflects the degree of peri-
toneal carcinomatosis, and is strongly correlated with the
CC. In contrast to HPCI, LPCI had the advantage of higher
CC0-1 resection rate. In this study, the median PCI was 15,
29 patients (58%) with LPCI and 21 patients (42%) with
HPCI, the median OS for LPCI vs. HPCI was 21.0 months
vs. 9.2 months. Similar to most other studies, LPCI signifi-
cantly improved the survival of patients.10,12,32,33 Our results
also suggest that HPCI patients could get smaller benefit
from CRSþHIPEC. Therefore, a sensible treatment strategy
for HPCI patients could be to reduce the tumor burden as
much as possible by CRSþHIPEC so as to improve OS.
The detection of preoperative serum TM was necessary.
In this study, 27 patients (54%) had elevated serum CEA,
CA125 and CA199 levels alone or in combination before
CRSþHIPEC. The median OS for preoperative TM (N)
vs. TM (AN) was 26.0 months vs. 8.8 months. For GC
PC patients, the TM (AN) indicated a poor prognosis.
Serum CEA, CA125 and CA199 levels could reflect tumor
invasiveness,38 peritoneal free tumor cells in the ascites,39
Table 4
Major studies on CRSþHIPEC, either single/multi-institutional, controlled studies or a systematic review.
Author/Years n CRSþ
HIPEC
(n or %)
HIPEC procedure Median OS of
CC (n or %, mo)
Median OS of
PCI (n or
%, mo)
Median
OS (mo)
Morbidity Mortality 1-yr OS rate 2-yr OS
rate
3-yr
OS rate
5-yr OS rate
Fujimoto
et al., 1997,
[34]
66 48 MMC 10 mg/mL
added in 3- to 4-L
Maxwell solution
at 39e48 C for
120 min. Open
HIPEC.
NR NR NR NR NR 54.0% NR 41.5% 31.0%
Yonemura
et al., 2001,
[35]
139 HIPEC1: 48
HIPEC2: 47
MMC 30 mg þ
DDP 300 mg
for 60 min.
Open HIPEC
HIPEC1: at
42e43.5 C
HIPEC2:
at 37 C
NR NR NR HIPEC1: 19%
HIPEC2: 14%
CRS: 19%
HIPEC1: 4%
HIPEC2: 0
CRS: 4%
NR NR NR HIPEC1: 61%
HIPEC2: 43%
CRS: 42%
Glehen et al.,
2004, [30]
49 49 MMC 40e60 mg
added in 4-
to 6-Lperfusate
at 46e48 C for
90 min. Closed
HIPEC.
CC0-1: 25/
21.3 (51.0%)
CC2: 24/6.1
(48.9%)
NR 10.3 27% 4% 48.1%
CC0-1: 74.8%
CC2: 15.8%
19.9%
CC0-1:
36.8%
CC2: 0%
NR 16.0%
CC0-1: 29.4%
CC2: 0%
Yonemura
et al., 2005,
[31]
107 107 MMC 30 mg þ
DDP 300 mg þ
etoposide 150 mg
at 42e43 C.
Open HIPEC.
CC0-1: 47/
19.2 (43.9%)
CC2-3: 60/
7.8 (56.1%)
NR 11.5 21.5% 2.8% NR NR NR 6.7%
CC0: 13.0%
CC1-3: 2.0%
Yang
et al., 2010,
[12]
28 30 HCPT 20 mg
or DDP 120 mg,
and MMC 30 mg
added in 12 L normal
saline for 90e120 min
at 41  0.5 C.
Open HIPEC.
CC0: 11/
43.4 (39.2%)
CC1: 6/
9.4 (21.4%)
CC2-3: 11/
8.3 (39.2%)
Median
PCI:13
20: 18/
27.7 (64.3%)
>20: 10/
6.4 (35.7%)
9.6 14.3% 0 NR NR NR NR
Glehen et al.,
2010, [9]
159 159 MMC 30e50 mg/m2
 DDP 50e100 mg/m2
for 60e120 min at
41e42.5 C; OX
360e460 mg/m2
 IR 100e200 mg/m2
 I.V.5-FU and
leucovorin for 30 min
and 43 C. Closed
or open HIPEC.
CC0: 85/
15.0 (56.0%)
CC1: 37/
6.0 (25.2%)
CC2: 30/
4.0 (18.8%)
Mean PCI：
9.4 (SD: 7.7)
9.2 27.8% 6.5% 43%
CC0: 61.0%
CC1: 31.0%
CC2-3: 4.0%
NR 18%
CC0: 31.0%
CC1: 5.0%
CC2-3: 3.0%
13%
CC0: 23.0%
CC1: 3.0%
CC2-3: 3.0%
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Table 4 (continued )
Author/Years n CRSþ
HIPEC
(n or %)
HIPEC procedure Median OS of
CC (n or %, mo)
Median OS of
PCI (n or
%, mo)
Median
OS (mo)
Morbidity Mortality 1-yr OS rate 2-yr OS
rate
3-yr
OS rate
5-yr OS rate
Macri et al.,
2011, [29]
30 30 MMC 3.3 mg/m2/
L þ DDP 25 mg/m2/
L for 60 min at
41e43 C. Open
HIPEC.
CC0: 26/(86.7%)
CC1: 3/(10.0%)
CC2: 1/(3.3%)
Mean PCI: 8.96 NR 23.0% 10% NR NR NR NR
Yang et al.,
2011, [10]
68 34 MMC 30 mg þ
DDP 120 mg added
in 6 L saline
solution for
60e90 min at
43 C. Open HIPEC.
CRS:
CC0-1: 20/11.0
(58.8%)
CC2-3: 14/4.0
(41.2%)
CRSþHIPEC:
CC0-1: 20/12.0
(58.8%)
CC2-3: 14/8.2
(41.2%)
Median PCI: 15
CRS:
20: 25/10.5 (73.5%)
>20: 9/3.0 (26.5%)
CRSþHIPEC:
20: 20/13.5 (58.8%)
>20: 14/10.2 (41.2%)
CRS: 6.5
CRS þ
HIPEC: 11.0
CRS: 11.7%
CRS þ HIPEC:
14.7%
0 CRS: 29.4%
CRS þ
HIPEC:
41.2%
NR CRS: 0
CRSþ
HIPEC:
5.9%
NR
Gill et al.,
2011, [37]
441 441 All of the above
HIPEC drugs
combination
modes.
CC0-1:/15.0
range 9.5e43.4
NR 7.9 (ranging
6.1e9.2)
21.5%
(ranging
9.6e55.6%)
4.8%
(ranging
0e14.3%)
43%
(ranging
22e68%)
18%
(ranging
11e50%)
NR 13%
Hultman et al.,
2013, [32]
18 8 Doxorubicin
15 mg/m2 þ
DDP 50 mg/m2
for 60e90 min
at 43 C. Open
HIPEC.
CC0: 6/19.1
(75%)
<9: 3/(37.5%)
9-18: 3/(37.5)
>18: 2/(25.0%)
14.3 62.5% 0 NR NR NR NR
Magge et al.,
2014, [33]
23 23 MMC 40 mg for
100 min at
42 C. Open
HIPEC.
CC0-1: 22/
(95.7%)
CC2: 1/(4.3%)
Median PCI: 10.5 9.5 52.2%
(60-d)
4.3% (66-d) 49.6% NR 17.9% NR
Rudloff et al.,
2014, [36]
17 9 OX 460 mg/m2
for 30 min at
41 C. Open
HIPEC.
CC0-1: 8/
12.0 (88.9%)
CC2: 1/4.0
(11.1%)
Median PCI: 5
20: 8/(89%)
>20: 1/(11%)
CRSþHIPEC:
11.3
SC: 4.3
8/9 or
88.9%
(90-d)
11.1% (90-d) NR NR NR NR
This study 50 52 LOB 50 mg/m2
þ Docetaxel
60 mg/m2 for
60 min at
43 C. Open
HIPEC.
CC0-1: 32/
23.5 64.0%)
CC2-3: 18/
8.0 (36.0%)
20: 29/21.0 (58.0%)
>20: 21/9.2 (42.0%)
14.3 23.1 0 58% 40% 32% NR
CRS: cytoreductive surgery; HIPEC: hyperthermic intraperitoneal chemotherapy; OS: overall survival; CC: completeness of cytoreduction; PCI: peritoneal cancer index; yr: year; MMC: mitomycin C; HCPT:
hydroxycamptothecin; DDP: cisplatin; OX: oxaliplatin; IR: irinotecan; LOB: lobaplatin; SD: standard deviation; NR: not reported; SC: systemic chemotherapy.
1
0
3
2
H
.-T.
W
u
et
a
l./E
JS
O
4
2
(2
0
1
6
)
1
0
2
4e
1
0
3
4
1033H.-T. Wu et al. / EJSO 42 (2016) 1024e1034and proliferative activity of tumor cells in ascites or pri-
mary tumor,40 respectively.
For CC score, compared to CC2-3, CC0-1 patients have
better survival benefit (Table 4). In our study, the median
OS for CC0-1 vs. CC2-3 was 23.5 months vs. 8.0 months.
To achieve maximal CRS including multi-organs and peri-
toneal areas resection, the field of operation should be wide.
However, extensive surgery means high potential morbidity
and mortality. In our study, the median operation time
400 min, surgical procedures-organ and peritoneal area
resection, including 1e3 organs (n ¼ 35, 76.6%) and
4e10 organs (n ¼ 11, 23.9%), 1e3 peritoneal areas
(n ¼ 31, 62.0%) and 4e10 peritoneal areas (n ¼ 19,
38.0%). This will directly increase the risk of bleeding, hy-
poproteinemia, fluid losses, electrolyte and hemodynamic
disturbances, anastomotic leakage, and infection, all
contribute to the increased morbidity and mortality rate
(Table 4). Therefore, intensive perioperative risk factors
management is warranted.
Postoperative adjuvant chemotherapy is also important
factor for long-term survival. All the 50 patients received
SC except 6 patients, and 22 cases had SCþIP chemo-
therapy. SCþIP could have double effects on PC nodules
from a bi-direction approach, which has been proved to
improve the survival.41,42 The median OS for postoperative
chemotherapy 6 cycles vs. <6 cycles was 26.0 months vs.
8.0 months. Therefore, the patients receive chemotherapy
to reduce residual tumor load after surgery.
In our experience, multivariate analysis identified that
CC0-1, perioperative TM (N), adjuvant chemotherapy 6
cycles were the independent predictor for better survival. Ac-
cording to these indicators, under the safety of surgery cir-
cumstances, we could select more accurate patients such as
TM (N), LPCI during preoperative assessment, maximal
CRS during operation, and strengthening SC and/or IP after
operation, who may benefit from the treatment.
The limitations of this study should be acknowledged. One
is the small sample size. In this study, 50 patients were treated
with 52 CRSþHIPEC procedures. A larger sample size could
be more preferable. The other limitation is the absence of
objective quality of life (QOL) data. We assessed the patient
wellbeing based on patient clinical symptoms and self-
reports, which are subjective and not comparable. In future
clinical studies, standard QOL scale should be used to make
the evaluation more objective and comparable.
In conclusion, CRSþHIPEC with lobaplatin and doce-
taxel to treat selected GC PC could improve OS, with
acceptable perioperative safety. Large sample, multi-
center clinical studies are required to obtain more
convincing evidence to validate this comprehensive thera-
peutic strategy.
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